Biogen Idec Lobbying Efforts

I pay about $1,800 a month for Avonex. Here's one way Biogen spent $1.2 million, paying lobbying firms.

Pharmaceuticals spent $226,999,560 on lobbying last year.

All I can say is F*CK Them!

Blogged with the Flock Browser

Tags:

April 10, 2008 in antegren , avonex, follow the money..., politics, tysabri | Permalink | Comments (0)

Rare Disease Linked to MS Drug Worries FDA

The risk of a rare brain disease and other infections remains the primary concern of federal regulators as they seek independent advice on whether to allow a promising multiple sclerosis drug back on the market, according to documents released Monday.

More here.

 

March 6, 2006 in tysabri | Permalink | Comments (0)

Multiple Sclerosis - TYSABRI� Update

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that their ongoing safety evaluation of TYSABRI� (natalizumab) has led to a previously diagnosed case of malignant astrocytoma being reassessed as progressive multifocal leukoencephalopathy (PML), in a patient in an open label Crohn's disease clinical trial.

More here.

April 2, 2005 in tysabri | Permalink | Comments (0)

Elan shares dive on drug setback

Shares in Irish drugmaker Elan have plummeted once more after a third case of disease linked to Tysabri, its multiple sclerosis treatment.

Elan suspended the drug after two patients were found to have caught the rare disease, one of whom later died.

The newly revealed case - which also ended with the death of the patient - could mean Tysabri never makes it back onto the market, analysts warned.

By the close of trading, Elan shares were down 56% to 2.43 euros.

More here.

March 31, 2005 in follow the money..., stocks, tysabri | Permalink | Comments (0)

Second death may doom multiple sclerosis drug

Cambridge life-sciences company Biogen Idec Inc. last night was plunged deeper into crisis by news that yet another patient taking its troubled Tysabri drug had died of the rare condition PML.     


That's the third patient discovered to have developed PML, a neurological disorder, while taking Tysabri and the second to die from the disease. ``This is a worst-case scenario,'' Sanford C. Bernstein analyst Geoffrey Porges said last night. ``There is now a 1-in-10 chance that this drug ever comes back.''

More here.

 

March 31, 2005 in antegren , avonex, bummer, tysabri | Permalink | Comments (0)

Tysabri Is No Vioxx

And more.

March 2, 2005 in tysabri | Permalink | Comments (0)

The Virus That Took Down Tysabri

The multiple sclerosis drug Tysabri might have squashed competition from some of the world's biotech giants, but in the end it was pushed off the market by a virus smaller than the tiniest transistors on any computer chip.

More here.

March 2, 2005 in tysabri | Permalink | Comments (0)

Biogen Idec Turns to Expert for Tysabri Help

To get answers about why two patients taking its new multiple sclerosis drug Tysabri apparently came down with a rare, often deadly brain disease, Biogen Idec Inc. of Cambridge is turning to Dr. Igor J. Koralnik, a 42-year-old neurologist at Beth Israel Deaconess Medical Center who may know more about the disease than anyone else.

More here.

March 2, 2005 in antegren , tysabri | Permalink | Comments (0)

Biogen, Elan Voluntarily Withdraw MS Drug

More info here.

February 28, 2005 in antegren , avonex, bummer, economy, follow the money..., tysabri | Permalink | Comments (0)

Biogen, Elan Suspend Tysabri After Death

Biogen Idec and Elan Corporation Plc on Monday suspended sales of their much-heralded new multiple sclerosis drug Tysabri after a patient died from a rare but frequently fatal central nervous system disease.

More here.

February 28, 2005 in antegren , bummer, follow the money..., treatment, tysabri | Permalink | Comments (0)